{
  "turn_global_index": 238,
  "session_index": 22,
  "session_id": "ultrachat_251049",
  "turn_in_session": 5,
  "date": "2023/05/29 (Mon) 05:39",
  "role": "assistant",
  "content": "Sure. The stem cell therapy being developed by Xintela for knee osteoarthritis is called XSTEM. It uses stem cells that have been modified to express a specific integrin that enables them to home in on the site of cartilage damage in the knee joint, where they can promote tissue repair and regeneration.\n\nThe XSTEM stem cells are derived from bone marrow and are modified to express the integrin alpha10. This integrin allows the stem cells to selectively bind to the damaged area of cartilage in the knee joint and promote the formation of new cartilage tissue.\n\nTo develop this therapy, Xintela conducted preclinical trials to establish its safety and efficacy in animal models. Based on positive results, the company has now obtained regulatory approval to conduct a clinical trial for XSTEM in humans with knee osteoarthritis.\n\nThe clinical trial will be a randomized, double-blind, placebo-controlled study involving around 48 patients with moderate to severe knee osteoarthritis. The primary endpoint of the trial will be the safety and tolerability of the therapy, as well as its efficacy in reducing pain and improving joint function.\n\nThe potential benefits of XSTEM stem cell therapy for knee osteoarthritis could be significant. Current treatment options for knee osteoarthritis include pain management, physical therapy, and joint replacement surgery. These treatments are often ineffective or carry significant risks, and can result in prolonged recovery times and loss of mobility for patients.\n\nIf successful, XSTEM stem cell therapy could provide a safe, effective, and minimally invasive treatment option for knee osteoarthritis that promotes tissue repair and regeneration, relieves pain, and improves joint function.",
  "has_answer": false
}